FDA Doesn't Approve Summit Therapeutics' China-Developed Lung Cancer Drug
Key Points:
- Investor’s Business Daily (IBD) provides information solely for educational and informational purposes, not as investment advice or recommendations to buy or sell securities.
- The data presented is sourced from what IBD believes to be reliable, but accuracy, timeliness, and suitability are not guaranteed.
- Past investment performance shared by IBD does not predict or ensure future results.
- Authors and presenters may hold positions in the stocks they discuss, and IBD makes no warranties regarding the advisability of any investment or strategy.
- Real-time prices are provided by Nasdaq Last Sale and ownership data by LSEG, with all information subject to change without notice; all trademarks mentioned are owned by Investor’s Business Daily, LLC.